Search

Your search keyword '"Nanda, R."' showing total 1,504 results

Search Constraints

Start Over You searched for: Author "Nanda, R." Remove constraint Author: "Nanda, R."
1,504 results on '"Nanda, R."'

Search Results

5. Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

6. Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

9. Atomistic Level Process to Device Simulation of GaNFET Using TNL TCAD Tools

10. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

11. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

15. Ecological status of threatened mangroves Ceriops decandra and Merope angulata in mangrove ecosystem Segara Anakan Lagoon, Central Java, Indonesia

18. 360[supercript 0] Approach to Assessing Cross-Cultural Intelligence: Use of Film

19. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

37. 205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

38. P253 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER+/human epidermal growth factor receptor 2 (HER2)- breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

39. Advanced Organic Chemistry Applications

41. Sampling bias in entrepreneurial experiments

42. Distribution of macro plastic debris in Muaragembong coastal bay during the east moonson and the east to west monsoon transition in 2020

43. May 2016 critical care case of the month

46. A novel biomarker to predict DNA-Repair-inhibitor response in stage I-III high risk breast cancer patients

48. LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial

Catalog

Books, media, physical & digital resources